Pharmaceuticals News and Research

RSS

Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 positive patients

Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter International Inc. today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011.

From Baxter International Inc. 21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

Covidien second quarter net sales up 10% to $2.80 billion

Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.

21 Apr 2011

ICON first quarter net revenue increases 4.6% to $229 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.

21 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Watson Laboratories seeks FDA approval to market Colesevelam HCI tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Colesevelam HCI 625 mg tablets.

21 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

RTCA HT instrument from Roche employs high-throughput real-time cell analysis

The new xCELLigence RTCA HT Instrument from Roche (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product.

21 Apr 2011

Shanghai Pharmaceutical and Pfizer enter MOU to pursue potential business opportunities

Shanghai Pharmaceutical Co. Ltd. and Pfizer Inc. today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China.

21 Apr 2011

ACT seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD).

21 Apr 2011

Stepped up measures to tack rising painkiller abuse

Prescription drug abuse is one of the largest problems in the country say experts and according to White House drug Czar Gil Kerlikowske, the Congress must require special training for doctors and other health care workers before they are allowed to prescribe powerful drugs such as OxyContin.

20 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Pharmaceuticals News and Research

Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 positive patients

Repligen anticipates 30% increase in total revenues for 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Alexion first quarter non-GAAP net income increases to $56.3 million

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Covidien second quarter net sales up 10% to $2.80 billion

ICON first quarter net revenue increases 4.6% to $229 million

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Watson Laboratories seeks FDA approval to market Colesevelam HCI tablets

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

RTCA HT instrument from Roche employs high-throughput real-time cell analysis

Shanghai Pharmaceutical and Pfizer enter MOU to pursue potential business opportunities

ACT seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD

Stepped up measures to tack rising painkiller abuse

Prism Pharmaceuticals to be acquired by Baxter

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Clontech releases iDimerize inducible dimerization systems

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence